Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoid Heart Disease × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 12 Carcinoid Tumor 5 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

telotristat ethyl 1 lutetium Lu 177 dotatate 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡